Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin
Category: #health  By Mateen Dalal  Date: 2019-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin

The new data further supports the potential of Dance 501 inhaled insulin in Type 2 diabetes patients

Dance Biopharm Holdings, Inc has recently presented Phase 2 Samba 04 clinical study results for its preservative free inhaled human insulin, Dance 501, for the treatment of Type 2 diabetes. Dance Biopharm is a privately-owned clinical stage biopharma company fully focused on the development of a new soft mist inhalable biologic formulations for those people suffering from chronic diseases.

Seemingly, in the results Dance 501 showed a faster onset of action for as compared to similar doses of subcutaneously administered insulin lispro. These findings were to be presented at the 79th Scientific Sessions of the American Diabetes Association, being organized in San Francisco.

According to Anne Whitaker, the chief executive officer of Dance Biopharm, the company’s presentation at ADA underscores ongoing commitment of Dance to develop advanced and patient-focused inhaled therapies that result to better health outcomes for people suffering with chronic diseases like diabetes.

Whitaker said that the new data further supports the potential of Dance 501, inhaled preservative free human inhaled insulin, which is an alternate treatment to injectable insulin for diabetes. These data determine the outstanding performance of soft mist inhaler platform and encourages the company to swiftly progress the development of its innovative soft mist biologics portfolio as treatments for chronic and severe diseases, Whitaker mentioned.

Sources familiar with the matter informed that this Phase 2 clinical trial, Samba 04, was designed as an open label, crossover, randomized, and active-comparator-controlled study that recruited 24 subjects with type 2 diabetes presently receiving metformin or insulin therapy. Each patient got three doses of subcutaneous insulin lispro and three doses of inhaled Dance 501 under medical administration or supervision.

Apparently, doses administered were 12, 24 and 48 U for both lispro and Dance 501. Each patient received all 6 doses during 6 visits that occurred 3 to 17 days apart. Using the automated glucose clamp method, insulin action was measured over a 10-hour period following dosing.

 

Source Credit: https://www.dancebiopharm.com/investors-and-media/press-releases/detail/18/dance-biopharm-presents-encouraging-data-from-phase-2

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...